600276 Jiangsu Hengrui Pharmaceuticals
- 43.81
- -0.94-2.10%
Jiangsu Hengrui Pharmaceuticals News
Hengrui Pharmaceutical (600276): The GLP-1 product portfolio was authorized to innovate overseas and implemented intensively
Incident: The company recently licensed the GLP-1 product portfolio with independent intellectual property rights to Hercules of the United States for a fee. As part of the consideration for the external licensing deal, the company will acquire Hercules 1
Hengrui Pharmaceutical's PD-1 overseas trip was temporarily thwarted, and progress lags behind Baekje and Junshi
Hengrui Pharmaceutical also pointed out in the announcement that due to uncertainty about the FDA's inspection of its production site and when to lift travel restrictions in some countries to complete the BIMO clinical examination, there is uncertainty about whether the marketing application will be approved.
Express News | Hengrui Pharmaceutical: Subsidiary SHR-1905 Injection Obtains Drug Clinical Trial Approval Notice
Hengrui Grants Rights to Bain Capital-Backed Company for Anti-Diabetes Treatment
Hengrui Pharmaceuticals (SHA:600276) granted Hercules CM Newco intellectual property rights to develop and sell a glucagon-like peptide-1 diabetes and weight loss treatment, according to a Friday fili
Hengrui Pharmaceuticals to Resubmit Marketing Application for Liver Cancer Drug Combination to US FDA
Jiangsu Hengrui Pharmaceuticals' (SHA:600276) plans to resubmit the marketing application for camrelizumab for injection combined with apatinib mesylate tablets to the US Food and Drug Administration,
Express News | China Merchants Securities resumed tracking Hengrui Pharmaceutical and rated strong purchases.
The company left the pipeline, capital paid, Hengrui Pharmaceutical's GLP-1 innovative drug team up to go overseas
Hengrui's overseas strategy and style of play seem to be evolving.
Express News | Hengrui Pharmaceutical: Received a complete response letter from the US FDA regarding injectable carelizumab
Hong Kong Stock Concept Tracking | Hengrui Pharmaceutical's GLP-1 Products Achieve Active Layout for Foreign Authorized Domestic and Foreign Companies (with Concept Shares)
The wave of research and development of GLP-1 drugs continues to heat up as market demand increases and the development of new drugs advances
Hengrui Pharmaceutical (600276): Which projects in the offshore pipeline can still be expected to go overseas?
This report first reviews Japanese pharmaceutical companies and confirms through specific cases that the revenue and potential share ratio of overseas markets under the license out model is an important source of revenue and profit elasticity for pharmaceutical companies. He then returned to Hengrui Pharmaceutical, the company
Creating a new model for going overseas? Hengrui packaged the GLP-1 product portfolio and reached a major BD deal with a US company
① Tonight, Hengrui Pharmaceutical announced that it reached a BD deal with a special company set up by several capital institutions in the US in May; ② The deal not only involved huge down payments and subsequent milestone payments and sales shares, but also included nearly 20% of the US company's shares; ③ The industry believes that Hengrui Pharmaceutical is joining forces with capital to create a new model for innovative drugs to go overseas, which can achieve a win-win situation for all parties, which is very novel.
Hengrui Pharmaceutical (600276.SH): Plans to license the GLP-1 product portfolio to Hercules of the United States for a fee
GLONGHUI May 16 丨 Hengrui Pharmaceutical (600276.SH) announced that the company will license the GLP-1 product portfolio with independent intellectual property rights to Hercules of the United States for a fee, and Hercules of the United States will obtain the exclusive right to develop, produce and commercialize the GLP-1 product portfolio on a global scale other than Greater China. As part of the consideration for the foreign licensing transaction, Hengrui will acquire 19.9% of the shares in Hercules of the United States and will obtain licensing fees for the GLP-1 product portfolio from Hercules of the United States. GLP-1 product portfolio
Hengrui Pharmaceuticals Plans Up to 1.2 Billion Yuan Share Buyback
Jiangsu Hengrui Pharmaceuticals (SHA:600276) plans to spend between 600 million yuan and 1.2 billion yuan to buy back shares, according to a filing with the Shanghai Stock Exchange. The repurchased sh
Express News | Hengrui Pharmaceutical: Will acquire 19.9% of the shares of Hercules in the United States
Hengrui Pharmaceutical (600276.SH): A total cost of 635 million yuan to buy back 0.22% of the shares
Gelonghui, May 15, 丨 Hengrui Pharmaceutical (600276.SH) announced that on May 14, 2024, the company's share repurchase period expired. The actual share repurchase was 14,351,878 shares, accounting for 0.22% of the company's total share capital. The highest transaction price was 47.01 yuan/share, and the minimum transaction price was 41.09 yuan/share. The average repurchase price was about 44.22 yuan/share, and the total transaction amount was 634,665,849.66 yuan (excluding transaction fees).
On May 15, A50ETF Huabao (159596) closed down 0.78% with a turnover of 154 million yuan. In terms of constituent stocks, only the Midea Group rose 2.8%. BYD fell 2.57%, Hengrui Pharmaceuticals fell 1.46%, CITIC Securities fell 1.37%, and all other individ
On May 15, A50ETF Huabao (159596) closed down 0.78% with a turnover of 154 million yuan. In terms of constituent stocks, only the Midea Group rose 2.8%. BYD fell 2.57%, Hengrui Pharmaceuticals fell 1.46%, CITIC Securities fell 1.37%, and all other individual stocks turned green. According to the news, the excellent performance of the recent A-share industry leading quarterly report became the focus of the market. The 2024 A-share industry leading quarterly report showed impressive performance, with 26 companies that achieved year-on-year growth in both revenue and net profit, accounting for more than 50%. China Merchants Securities's latest research report points out that this year's quarterly report confirmed the decline in the growth rate and freedom of A-share capital expenditure
Hengrui Pharmaceuticals Unit Gets China Clinical Trial Approval for Kidney Medication
China's medical products administrator approved Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Guangdong Hengrui Pharmaceutical's clinical trial for its SHR-2173 injection, according to a Wednesday
Hengrui Pharmaceutical (600276.SH): SHR-2173 injection received a notice of approval for drug clinical trials
Hengrui Pharmaceutical (600276.SH) announced that Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received the State Drug Administration...
Express News | Hengrui Pharmaceutical: Subsidiary obtains approval notice for drug clinical trials
Hehuang Pharmaceutical (00013.HK) and Hengrui Pharmaceutical reached a cooperation and initiated a phase II/III study on surufatinib (surufatinib) combined with camrelizumab (camrelizumab) in the treatment of primary pancreatic ductal adenocarcinoma
Gelonghui, May 14, 丨 Hehuang Pharmaceutical (00013.HK) announced the launch of a Chinese phase II/III clinical trial today to evaluate Hehuang Pharmaceutical's drug candidate surufatinib (surufatinib), the PD-1 antibody camrelizumab (camrelizumab) of Jiangsu Hengrui Pharmaceutical Co., Ltd. (“Hengrui Pharmaceutical”), albumin-conjugated paclitaxel (nab-paclitaxel), and gemcitabine (gemcitabine) for first-line treatment of metastatic pancreatic conduction Ductal adenocarcinoma (PDAC) patients
Analysis
Price Target
No Data
